Related Experiment Video
Updated: Jan 20, 2026
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Myocardial infarction and tuberculosis
Yuchen Li1, Qi Wu, Yingqing Chen
1Department of Internal Medicine, Haihe Hospital, Tianjin, China.
Insights
ST-elevation acute myocardial infarction (AMI) with active tuberculosis is rare. This study reports successful percutaneous coronary intervention (PCI) in three patients, demonstrating favorable outcomes despite bleeding risks.
Area of Science:
- Cardiology
- Infectious Diseases
- Pulmonology
Background:
- ST-elevation acute myocardial infarction (AMI) is a life-threatening condition.
- Active tuberculosis (TB) is a rare comorbidity in AMI patients.
- Percutaneous coronary intervention (PCI) is a standard treatment for ST-elevation AMI, but carries bleeding risks.
Observation:
- Three cases of ST-elevation AMI with active pulmonary tuberculosis were identified.
- These patients underwent PCI between July 2007 and September 2010.
- Anticoagulation and antiplatelet therapy posed potential risks for pulmonary hemorrhage.
Findings:
- All three patients with ST-elevation AMI and active TB achieved satisfactory outcomes after PCI.
- The study demonstrates the feasibility of PCI in this high-risk patient group.
- Careful management mitigated the risks associated with dual antiplatelet therapy and anticoagulation.
Implications:
- PCI can be a safe and effective treatment option for ST-elevation AMI patients with active tuberculosis.
- This finding challenges the notion of pulmonary TB as an absolute contraindication for PCI.
- Further research is warranted to establish optimal management strategies for this rare clinical scenario.
Abstract:
ST-elevation acute myocardial infarction (AMI) is a critical illness with a high mortality rate. Cases of AMI accompanied by active tuberculosis are rarely reported. Percutaneous coronary intervention (PCI) is an important procedure in the treatment of ST-elevation AMI; it can significantly improve the prognosis and quality of life and reduce mortality. Anticoagulants and antiplatelet medications are administered before, during, and after PCI. However, for patients with ST-elevation AMI accompanied by active tuberculosis, anticoagulation and antiplatelet therapy may lead to pulmonary haemorrhage, haemoptysis, and serious treatment difficulties. Some authors even regard pulmonary tuberculosis as a contraindication of PCI. In this study, we have reported 3 patients with ST-elevation AMI accompanied by active tuberculosis who underwent PCI at our hospital between July 2007 to September 2010, and obtained satisfactory outcomes.
Related Concept Videos
08:28Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice
09:45Histological Quantification of Chronic Myocardial Infarct in Rats
07:48Myocardial Infarction in Neonatal Mice, A Model of Cardiac Regeneration
12:03Myocardial Infarction and Functional Outcome Assessment in Pigs
07:45Acute Myocardial Infarction in Rats
08:23LAD-Ligation: A Murine Model of Myocardial Infarction